Cargando…

RCDOP方案治疗87例弥漫大B细胞淋巴瘤患者疗效分析

OBJECTIVE: To investigate the efficacy of RCDOP (Rituximab, cyclophosphamide, liposome doxorubicin, vincristine and prednisone) regimen in patients with de novo diffuse large B-cell lymphoma (DLBCL), especially in those patients with multiple extra-nodal involvement or Bulky diseases. METHODS: A tot...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342927/
https://www.ncbi.nlm.nih.gov/pubmed/30032566
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.06.010
_version_ 1783555636494073856
collection PubMed
description OBJECTIVE: To investigate the efficacy of RCDOP (Rituximab, cyclophosphamide, liposome doxorubicin, vincristine and prednisone) regimen in patients with de novo diffuse large B-cell lymphoma (DLBCL), especially in those patients with multiple extra-nodal involvement or Bulky diseases. METHODS: A total of 87 newly diagnosed DLBCL patients who received RCDOP regimen from October 2012 to October 2017 were enrolled into this study. Survival functions were estimated using the Kaplan-Meier method and compared by the log-rank test, and χ(2) tests were used for categorical data. RESULTS: Among the 87 DLBCL patients treated with RCDOP regimen, 81 patients achieved complete remission (CR) or partial remission (PR), with ORR as 93.1%. Patients were further classified into groups, according to the risk factors, such as IPI scores, multiple extra-nodal involvement, bulky disease, age>60, tumor Ki-67>80%, elevated serum LDH level and advanced Ann Arbor stage. The progression-free survival (PFS, P=0.084) and overall survival (OS, P=0.515) had no statistical difference among the IPI low risk (0–1 score) group, intermediate risk (2–3 scores) group and high risk (4–5 scores) group. Similarly, no statistical difference were fou nd in PFS and OS of patients with extra-nodal involvements ≥2 (P=0.303 and P=0.624), with bulky disease (P=0.518 and P=0.466), with age>60 (P=0.600 and P=0.183), with elevated serum LDH level (P=0.054 and P=0.880), with advanced Ann Arbor stage (P=0.075 and P=0.286), and with tumor Ki-67 over 80% (P=0.190 and P=0.109), when compared with those of patients without these risk factors. CONCLUSION: RCDOP can improve the therapeutic effect and prognosis of DLBCL patients with certain high risk factors, such as intermediate and high IPI risks, multiple extra-nodal involvements, bulky disease, age over 60, elevated LDH level, advanced Ann Arbor stage and tumor Ki-67 over 80%.
format Online
Article
Text
id pubmed-7342927
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73429272020-07-16 RCDOP方案治疗87例弥漫大B细胞淋巴瘤患者疗效分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To investigate the efficacy of RCDOP (Rituximab, cyclophosphamide, liposome doxorubicin, vincristine and prednisone) regimen in patients with de novo diffuse large B-cell lymphoma (DLBCL), especially in those patients with multiple extra-nodal involvement or Bulky diseases. METHODS: A total of 87 newly diagnosed DLBCL patients who received RCDOP regimen from October 2012 to October 2017 were enrolled into this study. Survival functions were estimated using the Kaplan-Meier method and compared by the log-rank test, and χ(2) tests were used for categorical data. RESULTS: Among the 87 DLBCL patients treated with RCDOP regimen, 81 patients achieved complete remission (CR) or partial remission (PR), with ORR as 93.1%. Patients were further classified into groups, according to the risk factors, such as IPI scores, multiple extra-nodal involvement, bulky disease, age>60, tumor Ki-67>80%, elevated serum LDH level and advanced Ann Arbor stage. The progression-free survival (PFS, P=0.084) and overall survival (OS, P=0.515) had no statistical difference among the IPI low risk (0–1 score) group, intermediate risk (2–3 scores) group and high risk (4–5 scores) group. Similarly, no statistical difference were fou nd in PFS and OS of patients with extra-nodal involvements ≥2 (P=0.303 and P=0.624), with bulky disease (P=0.518 and P=0.466), with age>60 (P=0.600 and P=0.183), with elevated serum LDH level (P=0.054 and P=0.880), with advanced Ann Arbor stage (P=0.075 and P=0.286), and with tumor Ki-67 over 80% (P=0.190 and P=0.109), when compared with those of patients without these risk factors. CONCLUSION: RCDOP can improve the therapeutic effect and prognosis of DLBCL patients with certain high risk factors, such as intermediate and high IPI risks, multiple extra-nodal involvements, bulky disease, age over 60, elevated LDH level, advanced Ann Arbor stage and tumor Ki-67 over 80%. Editorial office of Chinese Journal of Hematology 2018-06 /pmc/articles/PMC7342927/ /pubmed/30032566 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.06.010 Text en 2018年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
RCDOP方案治疗87例弥漫大B细胞淋巴瘤患者疗效分析
title RCDOP方案治疗87例弥漫大B细胞淋巴瘤患者疗效分析
title_full RCDOP方案治疗87例弥漫大B细胞淋巴瘤患者疗效分析
title_fullStr RCDOP方案治疗87例弥漫大B细胞淋巴瘤患者疗效分析
title_full_unstemmed RCDOP方案治疗87例弥漫大B细胞淋巴瘤患者疗效分析
title_short RCDOP方案治疗87例弥漫大B细胞淋巴瘤患者疗效分析
title_sort rcdop方案治疗87例弥漫大b细胞淋巴瘤患者疗效分析
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342927/
https://www.ncbi.nlm.nih.gov/pubmed/30032566
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.06.010
work_keys_str_mv AT rcdopfāngànzhìliáo87lìmímàndàbxìbāolínbāliúhuànzhěliáoxiàofēnxī
AT rcdopfāngànzhìliáo87lìmímàndàbxìbāolínbāliúhuànzhěliáoxiàofēnxī
AT rcdopfāngànzhìliáo87lìmímàndàbxìbāolínbāliúhuànzhěliáoxiàofēnxī
AT rcdopfāngànzhìliáo87lìmímàndàbxìbāolínbāliúhuànzhěliáoxiàofēnxī
AT rcdopfāngànzhìliáo87lìmímàndàbxìbāolínbāliúhuànzhěliáoxiàofēnxī
AT rcdopfāngànzhìliáo87lìmímàndàbxìbāolínbāliúhuànzhěliáoxiàofēnxī
AT rcdopfāngànzhìliáo87lìmímàndàbxìbāolínbāliúhuànzhěliáoxiàofēnxī